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S U M M A R Y
Objectives: To review the epidemiology of candidemia in a UK tertiary referral center.
Methods: Clinical and laboratory data from patients with candidemia were collected prospectively from
October 1, 2005 to June 30, 2008 (a 33-month period).
Results: A total of 107 episodes were identiﬁed. The incidence was 10.9 episodes/100 000 bed-days. The
most common predisposing factors were the use of broad-spectrum antibiotics (92%), the presence of an
intravascular device (IVD) (82%), admission to an intensive care unit (ICU) (51%), and recent surgery
(50%). Non-Candida albicans species accounted for 58% of the episodes, which is higher than the
percentage reported from other UK centers. C. albicans was the most common species, accounting for 43%
of episodes, followed by C. glabrata (31%) and C. parapsilosis (20%). Overall C. tropicalis, C. krusei, C.
norvegensis, and C. lusitaniae caused 7% of episodes. The crude 30-day mortality rate was 37%. Advanced
age (p = 0.003) and the presence of septic shock (p = 0.038) were associated with mortality.
Conclusions: Candidemia continues to be associated with a high mortality. Preventative measures
should be targeted against high-risk hospitalized patients, especially those in ICUs, the elderly, and those
undergoing major surgery. Local surveillance of candidemia is important to optimize management.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
The incidence of disseminated candidiasis including blood
stream infection has increased signiﬁcantly over the past
decades.1–4 Candida species are the most common cause of
invasive fungal infections in hospitalized patients and are the
fourth most common cause of nosocomial bloodstream infections
in the USA.5,6 Candidemia is associated with a prolonged hospital
stay, resulting in increased costs, and a high mortality of 25–
60%.3,7–14 Candida spp have been reported as the only organisms
that independently inﬂuence the outcome of nosocomial blood
stream infections (estimated odds ratio for mortality = 1.84).15
The epidemiology of candidemia is changing worldwide with
an increase in the proportion of non-Candida albicans species.3,16
Amongst most species causing bloodstream infections, ﬂuconazole
resistance is relatively uncommon, with the exception of Candida
glabrata.17 The clinical manifestations of invasive candidiasis are
non-speciﬁc, and the microbiological diagnosis remains a chal-§ Presented in part as ‘‘The pattern of candidaemia in a tertiary referral hospital in
the United Kingdom’’ (P1962) at the 19th European Congress of Clinical
Microbiology and Infectious Diseases, May 16–19, 2009, Helsinki, Finland.
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1201-9712/$36.00 – see front matter  2011 International Society for Infectious Disea
doi:10.1016/j.ijid.2011.06.006lenge with a high rate of false-negative blood culture results.18 The
value of other diagnostic tests remains controversial.
We investigated the epidemiology, predisposing factors, and
outcome of candidemia in our institution, with an aim to improve
the management of candidemia.
2. Patients and methods
University Hospitals Birmingham Foundation Trust is a 1200-
bed teaching hospital providing a wide range of services, including
acute medical and surgical care and regional and tertiary care for
burns, trauma, and orthopedic surgery, cancer, neurology/neuro-
surgery, cardiac surgery, and transplantation. There are no
obstetric/gynecology or pediatrics units in the Trust. The Trust
provides 54 000 admissions annually. There are four intensive care
units (ICU) with a total of 75 beds.
A prospective observational study of all cases of candidemia was
carried out from October 1, 2005 to June 30, 2008 (a 33-month
period). All episodes of candidemia were identiﬁed through the
laboratory computer system (TelePath). Data on the demographics
of patients, underlying medical conditions, information on immu-
nosuppression, results of relevant investigations, including inﬂam-
matory markers, and information on the details of antimicrobial
therapy were collected through the hospitalelectronic Prescribing
Information and Communication System (PICS) and clinicalses. Published by Elsevier Ltd. All rights reserved.
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followed-up until discharge/death. Clinical details, presence of an
intravascular device (IVD), and a history of major surgery in the 30
days prior to the occurrence of candidemia were collected through
the clinical microbiology records. Records of readmission and
outpatient visits, laboratory results following such events, and
outcome were searched through the PICS and the laboratory
computer system for a minimum period of 6 months following
discharge. No follow-up was undertaken in the absence of
readmission/outpatient visits following discharge. Data were
collected on a review form for each episode, which was subsequently
entered electronically onto a database (Excel, Microsoft).
Blood cultures were processed according to routine practice
using the automated blood culture system BACTEC 9240 (Becton
Dickinson, Sparks, MD, USA) and BacT/ALERT 3DTM (bioMe´rieux,
Marcy-l’Etoile, France; after 1 March 2008), with an average
incubation period of 5 days. No speciﬁc blood culture bottles were
used for the isolation of fungi. As part of the routine blood culture
processing service, BD BACTEC Plus Aerobic/F* and BD BACTEC
plus Anaerobic/F* bottles were used for the BACTEC system,
whereas BacT/ALERT SA and BacT/ALERT SN bottles were used for
the BacT/ALERT system. Blood cultures were incubated for a
period of 14 days when speciﬁc information including the
possibility of fungal infection or the presence of antifungal
therapy was provided with the microbiology request form. No
terminal subculture was undertaken, according to routine
practice. A positive blood culture with yeasts on Gram staining
was subcultured onto Can 2 plates (bioMe´rieux, Marcy-l’Etoile,
France). Isolates were identiﬁed as C. albicans with speciﬁc colored
colonies. Non-C. albicans isolates were speciated by a commercial
identiﬁcation system, Candida Auxacolor 2 (Bio-Rad, Marnes-la-
Coquette, France) or API 20C Aux (bioMe´rieux, Marcy-l’Etoile,
France). Those isolates that could not be identiﬁed by the above
systems were sent to the Mycology Reference Laboratory (Bristol,
UK).
Antifungal susceptibility tests were performed by the Mycology
Reference Laboratory. Interpretive criteria used for ﬂuconazole,
itraconazole, voriconazole, and caspofungin were in accordance
with the Clinical and Laboratory Standards Institute guidelines
(CLSI, Wayne, PA, USA). For amphotericin, the interpretation was
based on expert opinion.
2.1. Statistical analysis
Categorical variables were compared between groups with
Fisher’s exact test and continuous variables with the Kruskal–
Wallis test. Stepwise binary logistic regression analysis, with
mortality as the dependent variable, was used for multivariable
analysis, and the results are presented as estimated odds ratio (OR)
with associated 95% conﬁdence intervals (CI) and p-values. All
statistical analyses were performed with SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL, USA).
2.2. Deﬁnitions
At least one blood culture with growth of Candida spp was
included as an episode of candidemia. An additional episode of
candidemia 2 weeks after the previous episode with resolution of
clinical features of sepsis in the intervening period was considered
as a separate episode.
An IVD was deﬁned as the focus of candidemia if a Candida
species was grown from an IVD tip (when received by the
laboratory) during an episode of candidemia.
Neutropenia was deﬁned as an absolute neutrophil count 0.5 
109/l. Septic shock was deﬁned in the presence of a systolic blood
pressure of <90 mmHg, a diastolic blood pressure of <60 mmHg, orﬂuid/inotrope requirement to maintain a blood pressure above these
levels.
Antifungal therapy was deﬁned as inappropriate if the isolated
Candida spp was resistant or likely to be resistant (i.e., ﬂuconazole
for Candida krusei) to the chosen antifungal agent, or if an active
antifungal agent was used with inadequate dosages (<400 mg of
ﬂuconazole/day). Therapy with an inadequate dose of an antifun-
gal agent with an intermediate/dose-dependent susceptibility to
the isolated Candida spp was also deﬁned as inappropriate.
Candidemia as the attributed cause of death: this was deﬁned in
the presence of continuing sepsis leading up to the death and the
lack of isolation of another pathogen.
3. Results
One hundred and seven episodes of candidemia were identiﬁed
in 102 patients. The rate of candidemia was 10.9 episodes/100 000
bed-days. Candidemia was detected at a median of 14 days
following hospital admission. Patient baseline characteristics and
clinical details stratiﬁed by Candida spp are reported in Table 1. The
median patient age was 55 years (for all episodes). Most episodes
of candidemia were hospital-acquired (n = 94, 88%). Fifty-ﬁve (51%)
episodes were associated with the ICUs. Immunocompromised
conditions and neutropenia were uncommonly associated with
candidemia (Table 1). Most episodes were associated with surgical
specialties (n = 67, 63%). In this group, gastrointestinal (GI) surgery
was the predominant specialty (18 of 67, 27%), followed by cardiac
surgery (15 of 67, 22%). Most patients had previously been exposed
to broad-spectrum antibiotics (n = 98, 92% episodes).
Patients presented with septic shock in 14 (13%) episodes. Nine
of the 14 episodes (64%) occurred in patients who were admitted to
ICUs. No appropriate empirical antifungal therapy was initiated for
any of the above episodes.
The time interval to detection of candidemia following
collection of a blood culture sample varied widely from 0 to 8
days, with a median of 2 days (interquartile range 2–3 days).
The distribution of Candida spp is shown in Figure 1. One of the
107 candidemia episodes was caused by a mixture of two types of
Candida spp. C. albicans was the most common species isolated
(n = 46, 43%), followed by C. glabrata (n = 33, 31%) and Candida
parapsilosis (n = 21, 20%). Non-Candida albicans species accounted for
58% of the episodes. Overall, C. tropicalis, C. krusei, C. norvegensis and C.
lusitaniae caused 7% of the episodes. There was no difference
between the major Candida spp in relation to age of patients
(p = 0.26), sex (p = 0.13), presence of an IVD (p = 0.07), history of
recent surgery (p = 0.09), or severity of sepsis (p = 0.45). The
following signiﬁcant differences were found across the Candida
spp: C. albicans was the most common species associated with ICU
infections (p = 0.035); C. glabrata was most commonly associated
with GI tract disease (p = 0.015) and least often with an IVD focus
(p = 0.003) and with burns (p = 0.029). In 56 (52%) episodes,
colonization with a Candida spp was evident around the time of
candidemia.
Overall resistance to antifungal agents was low. Resistance to
amphotericin was not detected in any of the Candida strains. All C.
albicans isolates were susceptible to amphotericin, voriconazole,
ﬂuconazole, itraconazole, and caspofungin. Overall 89/106 (84%)
Candida strains were susceptible to ﬂuconazole and 15/106 (14%)
strains exhibited dose-dependent susceptibility (or intermediate
susceptibility) to ﬂuconazole. Resistance to ﬂuconazole was
detected in two strains (one C. glabrata and one C. krusei). Dose-
dependent (or intermediate) susceptibility to ﬂuconazole was
detected in 13/33 (39%) C. glabrata strains.
Appropriate antifungal therapy was initiated irrespective of
timing in 87 (81%) episodes, and in 72 (67%) episodes the therapy
was continued for a minimum period of 7 days; there were
Table 1
Demographics clinical characteristics, antifungal therapy, and outcome of candidemia by the three most common Candida species
Characteristic All episodes
(n = 107)
C. albicansa
(n = 45)
C. glabrata
(n = 33)
C. parapsilosis
(n = 21)
p-Valueb
Median age (range), years 55 (17–95) 56 (19–95) 58 (23–89) 46 (17–82) 0.26
Male 52 (49) 20 (44) 21 (64) 8 (38) 0.13
Female 55 (51) 25 (56) 12 (36) 13 (62) 0.13
Hospital-acquired 94 (88) 42 (93) 29 (88) 15 (71) 0.052
ICU-acquired 55 (51) 29 (64) 12 (36) 9 (43) 0.035
Any underlying conditionc 90 (84) 35 (78) 28 (85) 20 (95) 0.22
Diabetes 18 (17) 7 (16) 5 (15) 4 (19) 0.88
Malignancy 31 (29) 12 (27) 11 (33) 5 (24) 0.74
GI tract disease 36 (34) 10 (22) 18 (55) 7 (33) 0.015
Immunocompromised 16 (15) 5 (11) 8 (24) 2 (10) 0.24
Neutropenia 4 (4) 1 (2) 2 (6) 0 0.59
Burns 10 (9) 7 (16) 0 3 (14) 0.029
Chronic renal failure 11 (10) 3 (7) 5 (15) 3 (14) 0.38
Recent surgery 53 (50) 26 (58) 16 (48) 6 (29) 0.09
IVD in situ 88 (82) 38 (84) 22 (67) 19 (90) 0.07
IVD – focus of infection 40 (37) 22 (49) 5 (15) 11 (52) 0.003
Severe sepsis and septic shock 14 (13) 4 (9) 6 (18) 2 (10) 0.45
Appropriate antifungal therapy initiated 87 (81) 43 (96) 21 (64) 16 (76) <0.001
Appropriate therapy completed (minimum 7 days) 72 (67) 36 (80) 16 (48) 15 (71) 0.013
Appropriate empirical therapy started within 24 h of collection of blood culture 16 (15)d 9 (20) 3 (9) 4 (19) 0.43
Crude mortality
Death within 7 days of candidemia 21 (20) 7 (16) 11 (33) 2 (10) 0.07
Death within 30 days of candidemia 40 (37) 13 (29) 19 (58) 6 (29) 0.025
Attributable mortality
Death within 7 days of candidemia 16 (15) 5 (11) 8 (24) 2 (10) 0.24
Death within 30 days of candidemia 23 (21) 6 (13) 11 (33) 4 (19) 0.12
ICU, intensive care unit; GI, gastrointestinal; IVD, intravascular device. All numbers in brackets represent percentages unless stated otherwise.
a One episode with mixed growth of C. albicans and C. krusei is excluded.
b Wherever there is a signiﬁcant difference between the three species, C. albicans and C. glabrata are signiﬁcantly different. In addition, for IVD as the focus of infection, C.
glabrata and C. parapsilosis are signiﬁcantly different, and for antifungal therapy, C. albicans and C. parapsilosis are signiﬁcantly different.
c Includes the presence of chronic heart or lung disease or any of the medical conditions speciﬁed below.
d One patient was already on appropriate antifungal therapy as a result of previously detected candidemia from the transferring hospital.
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(15%) episodes was appropriate antifungal therapy initiated within
24 h of collection of the ﬁrst set of blood cultures with a Candida
species. The following antifungal agents were used either as the
sole agent throughout the course of treatment, or in a sequential
pattern resulting in the use of multiple agents for a single episode:
ﬂuconazole was used most often (n = 65, 61%), followed by
amphotericin B-based preparations (n = 30, 28%), caspofungin
(n = 31, 29%), and voriconazole (n = 8, 7%). Amphotericin lipid
formulations were mostly used amongst the amphotericin B group
(n = 28, 93%).
In 88 (82%) episodes, an IVD was in situ at the time of
candidemia; implanted IVDs were in situ in 23 (26%) of these
episodes. In the presence of an IVD, advice was given for its
removal and this was implemented whenever possible. The IVDs
were removed in 78/87 (90%) cases, but only 73 of the 87 (84%)Figure 1. Distribution of Candida species (*C. krusei and C. albicans).tips were received by the laboratory. Candida spp were isolated
from the IVD tips in 40 (37%) episodes, therefore conﬁrmed as
the foci of candidemia. In 10 episodes, no record of a removal of
the IVD was available. In ﬁve of these patients the reasons for
failure to remove IVDs were as follows: one patient was already
diagnosed to have endocarditis as the focus of candidemia, a
second patient was clinically suspected to have deep-seated
candidiasis of the oral cavity, a third patient died before
reporting of candidemia, the fourth patient was pre-morbid, and
the ﬁfth patient was hemodialysis-dependent with a poor
prognosis and difﬁcult vascular access. Three of the implanted
IVDs were not removed.
The 30-day crude mortality was 37% and the attributable
mortality was 21% (Table 1). The mortality rate in the group
receiving appropriate empirical antifungal therapy within 24 h of
collection of a blood culture positive for a Candida spp and in those
receiving therapy after a positive blood culture report was not
signiﬁcantly different.
Nine of the 14 (64%) episodes associated with septic shock
resulted in death at 30 days of candidemia (p = 0.037). Logistic
regression analysis identiﬁed the association of advanced age (OR
1.04, 95% CI 1.01–1.06; p = 0.003) and septic shock (OR 3.77, 95% CI
1.08–13.20; p = 0.038) with crude mortality at 7 days and 30 days.
The above analysis also revealed the association of advanced age
(OR 1.06, 95% CI 1.02–1.09; p = 0.003) and septic shock (OR 5.49,
95% CI 1.45–20.84; p = 0.012) with attributable mortality at 30
days. An association of a speciﬁc Candida spp with mortality was
not identiﬁed in the multivariable analysis.
Six patients (6%) had recurrent episodes of candidemia, of
whom ﬁve had the recurrences during the study period and one
after completion of the study period. One further patient had
persistent infection and died with an unresolving mediastinitis
following 12 weeks of candidemia.
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Because of the lack of sensitivity of blood cultures, estimates of
invasive candidiasis based on positive blood cultures are artiﬁcially
low. The epidemiology of candidemia with regards to the incidence
as well as Candida species distribution, varies markedly from
country to country as well as from region to region.19 Recent
reports on rates of candidemia have ranged from 0.2 to 0.5/1000
admissions and 0.31 to 1.4 episodes per 10 000 patient-
days.9,10,12,13,20,21 Our rate, which equates to 1.09 episodes/
10 000 bed-days, is higher than rates reported previously from
the UK and Europe.10,20,21 We noted a high incidence in the ICUs
(51%) and surgical specialties, especially from GI and cardiac
surgery. Although C. albicans was the predominant species, the
proportion of non-C. albicans species, particularly C. glabrata, was
higher than reported from other centers, including centers in the
UK.1,3,10,13,21
The 30-day crude mortality of 37% is higher than a recent report
from the USA, but similar to previous reports from Europe.9,10 Five
patients (5%) died within 24 h of blood culture collection and
before detection of candidemia. Death was attributed to candide-
mia in the above patients. Attributable mortality due to
candidemia has been shown to be signiﬁcant, ranging from 14%
to 49%.9,22 Both the crude and attributable rates of 37% and 21% in
our study are likely to be underestimations, as death following
transfer or discharge from the hospital was not searched for and
death occurring after 30 days of candidemia was not included in
this group. Similarly our recurrence rate of 6% is probably an
underestimation, as patients were not actively followed up
following discharge or transfer to another hospital. Moreover
relapse/recurrence without a positive culture for Candida was not
included in this group.
Our estimation of Candida colonization during an episode of
candidemia in 52% of the episodes may have been an underesti-
mation, as routine surveillance cultures for detection of micro-
organisms are not carried out in high-risk patients in our
institution. Similar to other studies, we noted a common
association of an IVD focus with candidemia.
An association of C. glabrata with advanced age and high
mortality has previously been reported.10,23,24 We observed an
association of underlying GI disease and lack of an IVD focus with
candidemia due to C. glabrata. The association of C. glabrata with
increased mortality was not evident in the multivariable analysis
in our study.
C. albicans has been reported by others to be associated with a
high mortality.3,23 In contrast to these reports, multivariable
analysis in our study showed a lack of association of a speciﬁc
Candida spp with mortality.
The absence of antifungal therapy has been associated with
higher mortality in various studies.3,12,24 A delay in initiation of
ﬂuconazole therapy in hospitalized patients with candidemia has
also been shown to result in a signiﬁcantly high mortality.25,26 Our
observation of the lack of association of mortality with delay in
initiation of antifungal therapy may have been due to the small
number of patients receiving appropriate empirical antifungal
therapy (n = 14, 13%). We noted an association of septic shock with
mortality in the multivariable analysis. None of the patients with
septic shock had received appropriate empirical antifungal
therapy. This observation combined with the delay in the
laboratory detection of candidemia highlights the need for
heightened awareness of invasive candidiasis/candidemia and
the timely initiation of antifungal therapy in high-risk groups.
In conclusion, we observed candidemia as mostly hospital-
acquired and an important cause of morbidity and mortality. The
epidemiology of candidemia is changing, with our observation of
non-C. albicans species as frequent causes of candidemia. IVDs,admission to the ICU, and recent major surgical procedures are
commonly associated with candidemia. Advanced age and presence
of septic shock are signiﬁcantly associated with mortality,
highlighting the need for awareness of candidemia and prompt
initiation of antifungal therapy in these groups. Local surveillance of
the epidemiology of candidemia is essential to identify subsets of
high-risk patients and the pattern of causative Candida spp in order
to formulate guidelines for optimal management.
Acknowledgements
We would like to acknowledge the assistance of the Mycology
Reference Laboratory, Bristol, UK in performing and interpreting
the antifungal susceptibility results.
Funding: No funding was provided for undertaking the study, for
writing up the report, or for the submission of the manuscript.
Conﬂict of interest: No conﬂict of interest declared.
References
1. Health Protection Agency. Voluntary surveillance of candidaemia in England,
Wales, and Northern Ireland 2007. Health Protection Report 2008; 2(38):
Healthcare Acquired Infections. London, UK: HPA; 2008. Available at: http://
www.hpa.org.uk/hpr/archives/2008/hpr3808.pdf (accessed July 2011).
2. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB.
Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from
a prospective nationwide surveillance study. Clin Infect Dis 2004;39:309–17.
3. Pappas PG, Rex JH, Lee J, Hamill RJ, Larsen RA, Powderly W, et al. A prospective
observational study of candidemia: epidemiology, therapy and inﬂuence on
mortality in hospitalized adult and pediatric patients. Clin Infect Dis
2003;37:634–43.
4. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of
candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol
2002;40:3489–92.
5. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial
fungal infections in the United States, 1980–1990: National Nosocomial Infec-
tions Surveillance System. J Infect Dis 1993;167:1247–51.
6. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP.
Nosocomial bloodstream infections in United States hospitals: a three year
analysis. Clin Infect Dis 1999;29:239–44.
7. Leleu G, Aergerter P, Guidet B. Colle`ge des Utilisateurs de Base de Donne´es en
Re´animation. Systemic candidiasis in intensive care units: a multicentre,
matched-cohort study. J Crit Care 2002;17:168–75.
8. Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Powe NR, Brower RG, et al.
Candida infections: outcome and attributable ICU costs in critically ill patients. J
Intensive Care Med 2000;15:255–61.
9. Zaoutis TE, Argon J, Chu J, Berlin J, Walsh T, Feudtner C. The epidemiology and
attributable outcomes of candidemia in adults and children hospitalized in the
United States: a propensity analysis. Clin Infect Dis 2005;41:1232–9.
10. Tortorano A, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidae-
mia in Europe: epidemiology and resistance. Int J Antimicrob Agents
2006;27:359–66.
11. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in
critically ill non-immunosuppressed patients. Lancet 2003;3:685–702.
12. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M.
Epidemiology and predictors of mortality in cases of Candida bloodstream
infection: results from population-based surveillance, Barcelona, Spain, from
2002 to 2003. J Clin Microbiol 2005;43:1829–35.
13. Schelenz S, Gransden WR. Candidaemia in a London teaching hospital: analysis
of 128 cases over a 7-year period. Mycoses 2003;46:390–6.
14. Hassan I, Powell G, Sidhu M, Hart WM, Denning DW. Excess mortality, length of
stay and cost attributable to candidaemia. J Infect 2009;59:360–5.
15. Pittet D, Li N, Woolson RF, Wenzel RP. Microbiological factors inﬂuencing the
outcome of nosocomial bloodstream infections: a 6 year validated, population-
based model. Clin Infect Dis 1997;24:1068–78.
16. Antoniadou A, Torres H, Lewis R, Thornby J, Bodey GP, Tarrand JP, et al.
Candidemia in a tertiary care cancer center: in vitro susceptibility and its
association with outcome of initial antifungal therapy. Medicine (Baltimore)
2003;82:309–21.
17. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group.
Twelve years of ﬂuconazole in clinical practice: global trends in species
distribution and ﬂuconazole susceptibility of bloodstream isolates of Candida.
Clin Microbiol Infect 2004;10(Suppl 1):11–23.
18. Edwards Jr J. Candida species. In: Mandell GL, Bennett JE, Dolin R, editors.
Mandell, Douglas and Bennett’s principles and practice of infectious diseases. 6th
ed., Philadelphia: Churchill Livingstone; 2005. p. 2938–57.
19. Falagas ME, Roussos N, Vardakas KZ. Relative frequency of albicans and the
various non-albicans Candida spp among candidemia isolates from inpatients
in various parts of the world: a systematic review. Int J Infect Dis
2010;14:e954–66.
I. Das et al. / International Journal of Infectious Diseases 15 (2011) e759–e763 e76320. Kibbler CC, Seaton S, Barnes RA, Gransden WR, Holliman RE, Johnson EM, et al.
Management and outcome of bloodstream infections due to Candida species in
England and Wales. J Hosp Infect 2003;54:18–24.
21. Odds FC, Hanson MF, Davidson AD, Jacobsen MD, Wright P, Whyte JA, et al. One
year prospective survey of Candida bloodstream infections in Scotland. J Med
Microbiol 2007;56:1066–75.
22. Gudlaugsson O, Gillespie S, Lee K, Berg JV, Hu J, Messer S, et al. Attributable
mortality of nosocomial candidemia, revisited. Clin Infect Dis 2003;37:1172–7.
23. Weinberger M, Leibovici L, Perez S, Samra Z, Ostfeld I, Levi I, et al. Characteristics
of candidaemia with Candida albicans compared with non-albicans Candida
species and predictors of mortality. J Hosp Infect 2005;61:146–54.24. Malani A, Hmoud J, Chiu L, Carver P, Bielaczyc A, Kauffman C. Candida
glabrata fungemia: experience in a tertiary care center. Clin Infect Dis
2005;41:975–81.
25. Garey K, Rege M, Pai M, Mingo D, Suda K, Turpin R, Bearden D. Time initiation of
ﬂuconazole therapy impacts mortality in patients with candidemia: a multi-
institutional study. Clin Infect Dis 2006;43:25–31.
26. Morrell M, Fraser V, Kollef M. Delaying the empiric treatment of Candida
bloodstream infection until positive blood culture results are obtained: a
potential risk factor for hospital mortality. Antimicrob Agents Chemother
2005;49:3640–5.
